Drug
Capecitabine clinical trials
Also written Xeloda, Ro 09-1978/000 and NSC-712807.
Counted the way a researcher would: Capecitabine with its salts, dosage forms, brands and biosimilars. Looking for a trial to join? Including related medicines shows more you could take part in.
This browser remembers your choice.
How each study uses Capecitabine is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Capecitabine studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 30 Apr 1998 · XELODA · NDA 020896 (FDA, Drugs@FDA)
- European Union
- 2 Feb 2001 · Xeloda · EMEA/H/C/000316 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Brand
- Xeloda
- 296
Studies by the year they started
942 studies that test it; most in 2004 (74); 2 more planned to start later
| Year | Studies |
|---|---|
| 1997 | 1 |
| 1998 | 3 |
| 1999 | 6 |
| 2000 | 9 |
| 2001 | 15 |
| 2002 | 39 |
| 2003 | 52 |
| 2004 | 74 |
| 2005 | 50 |
| 2006 | 66 |
| 2007 | 50 |
| 2008 | 46 |
| 2009 | 55 |
| 2010 | 41 |
| 2011 | 34 |
| 2012 | 24 |
| 2013 | 34 |
| 2014 | 24 |
| 2015 | 23 |
| 2016 | 25 |
| 2017 | 19 |
| 2018 | 27 |
| 2019 | 23 |
| 2020 | 37 |
| 2021 | 27 |
| 2022 | 28 |
| 2023 | 27 |
| 2024 | 32 |
| 2025 | 32 |
| 2026 | 19 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 128 · Other 820
Hoffmann-La Roche (42) · Fudan University (26) · Sun Yat-sen University (23) · M.D. Anderson Cancer Center (22) · National Cancer Institute (NCI) (19) · Alliance for Clinical Trials in Oncology (15) · Asan Medical Center (14) · Swiss Group for Clinical Cancer Research (12)
Often tested with
Tested in the same studies.
Oxaliplatin (226) · Bevacizumab (101) · Docetaxel (90) · Gemcitabine (76) · Irinotecan (65) · Cisplatin (57) · Fluorouracil (54) · Paclitaxel (44)
Related medicines
As reviewed, each with the page that says it.
- A prodrug of Fluorouracil source
- One of Antimetabolites source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Tested against it · 53 phase 3 studies under way
Capecitabine is the comparator. A study of two new drugs counts under both.
- 6Sacituzumab tirumotecan · Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., Merck Sharp & Dohme LLC · next primary completion Dec 2026
- 4Oxaliplatin · Pfizer, Zhai Wenlong · next primary completion Mar 2027
- 4Sacituzumab govitecan · Gilead Sciences, GBG Forschungs GmbH · next primary completion Dec 2026
- 3Fluorouracil · Pfizer, Zhai Wenlong · next primary completion Mar 2027
- 3Datopotamab deruxtecan · AstraZeneca · next primary completion Sep 2027
- 3Fulvestrant · Second Affiliated Hospital, School of Medicine, Zhejiang University, Herui Yao · next primary completion Dec 2028
- 3Izalontamab brengitecan · Sichuan Baili Pharmaceutical Co., Ltd., Bristol-Myers Squibb · next primary completion Mar 2028
- 2Irinotecan · Pfizer, CSPC Ouyi Pharmaceutical Co., Ltd. · next primary completion Jan 2028
Reaching primary completion within a year · 36, 1 in phase 3
Studies that test Capecitabine, phase 3 first.
- Nov 2026A Study Comparing BL-B01D1 With Physician's Choice of Chemotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma(PANKU-NPC01)Phase 3 · Sichuan Baili Pharmaceutical Co., Ltd.
- Nov 2026Trial Evaluating 3-year Disease Free Survival in Patients With Locally Advanced Rectal Cancer Treated With Chemoradiation Plus Induction or Consolidation Chemotherapy and Total Mesorectal Excision or Non-operative ManagementPhase 2 · Memorial Sloan Kettering Cancer Center
- Nov 2026Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast CancerPhase 2 · Stanford University
- Dec 2026Galunisertib Combined With Capecitabine in Advanced CRC With PMPhase 1/2 · The Netherlands Cancer Institute
- Dec 2026Sacituzumab Govitecan in Combination With Capecitabine for Advanced Gastrointestinal Cancers After Progression on Standard TherapyPhase 1 · Henry Ford Health System
- Dec 2026Capecitabine, Tucatinib, and Intrathecal Trastuzumab for Breast Cancer Patients With Leptomeningeal DiseasePhase 2 · UNICANCER
- Dec 2026Efficacy and Safety of Atezolizumab Plus Capecitabine Adjuvant Therapy for Triple Receptor-Negative Breast CancerPhase 2 · National Cancer Center, Korea
- Dec 2026Colon Neoadjuvant FOLFOXIRI StudyPhase 2 · Chinese University of Hong Kong
- Dec 2026Toripalimab Combined With Capecitabine as Postoperative Adjuvant Therapy for Patients With Resectable Advanced Extrahepatic Biliary Tract CancerPhase 2 · Tianjin Medical University Cancer Institute and Hospital
- Dec 2026Preoperative, Proton- Radiotherapy Combined With Chemotherapy for Borderline Resectable Pancreatic CancerNot applicable · EBG MedAustron GmbH
Studies
Open first, then newest update. How each study uses Capecitabine is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 948
- Gene Signatures to Guide HR+MBC Therapy in a Diverse CohortRecruitingPhase 2Sonya ReidNCT05693766Written as Capecitabine
- Pan Tumor Rollover StudyRecruitingPhase 2Bristol-Myers SquibbNCT03899155Written as Capecitabine
- Short Course Radiation Therapy and Combination Chemotherapy for the Treatment of Stage II-III Rectal CancerRecruitingPhase 1Jonsson Comprehensive Cancer CenterNCT04703101Written as Capecitabine
- Feasibility Study of Huangqi Yangyuan Formula for Capecitabine-Induced Adverse Reactions in Advanced Colorectal CancerNot yet recruitingNot applicableHuanfang FanNCT07913516Written as Capecitabine
- A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal AdenocarcinomaRecruitingPhase 2AstraZenecaNCT07069712Written as Capecitabine
- Selective Internal Radiation Therapy and Capecitabine (Chemotherapy) Treatment for Liver CancerRecruitingPhase 2Center Eugene MarquisNCT05265208Written as Capecitabine
- Fruquintinib Combined With Capecitabine as Adjuvant Extended Therapy After R0 Resection and Perioperative Chemotherapy in Patients With Liver-Only Metastatic Colorectal CancerNot yet recruitingPhase 3West China HospitalNCT07885384Written as Fruquintinib Combined With Capecitabine
- Conversion Therapy Plus Surgery and Radiotherapy for Retroperitoneal Nodal Metastases in Gastric CancerRecruitingPhase 2Jinbo YueNCT07007182Written as Capecitabine / S-1 (radiosensitizer during IMRT)
- A Single-arm, Prospective Phase Ⅱ Clinical Study of Utidelone Combined With Capecitabine in the Treatment of Active Brain Metastasis of TNBCRecruitingPhase 2Henan Cancer HospitalNCT06598046Written as Utidelone and capecitabine
- A Multicenter, Randomized, Controlled Phase III Clinical Trial on Adjuvant Intensified Therapy for Patients With Residual Disease After Neoadjuvant Treatment for Triple-negative Breast CancerNot yet recruitingPhase 3Shandong Cancer Hospital and InstituteNCT07869628Written as Capecitabine and PD-1 inhibitor
- CapTemY90 for Grade 2/3 NET Liver MetastasesRecruitingPhase 2Abramson Cancer Center at Penn MedicineNCT04339036Written as Capecitabine Oral Product
- NBTXR3, Chemotherapy, and Radiation Therapy for the Treatment of Esophageal CancerRecruitingPhase 1M.D. Anderson Cancer CenterNCT04615013Written as Capecitabine
- Phase II Single Arm Trial of Low Dose Capecitabine in Patients With Advanced Breast CancerRecruitingPhase 2University of Alabama at BirminghamNCT06105684Written as Capecitabine Pill
- Proton Radiation for Unresectable, Borderline Resectable, or Medically Inoperable Carcinoma of the PancreasRecruitingPhase 2Proton Collaborative GroupNCT02598349Written as Capecitabine
- Capecitabine in Low Risk Triple Negative Breast CancerRecruitingPhase 2Fudan UniversityNCT06787339Written as Capecitabine
- PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)RecruitingPhase 2Kristina A. FanucciNCT07222215Written as Capecitabine
- A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain MetastasesRecruitingPhase 2Biostar Pharma, Inc.NCT06764940Written as Utidelone in combination with capecitabine
- Capecitabine in ER+/HER2-negative Breast CancerRecruitingPhase 2University Health Network, TorontoNCT07631052Written as Capecitabine
- Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast CancerRecruitingPhase 2Stanford UniversityNCT04768426Written as Capecitabine
- Adaptive Therapy With Capecitabine for Treatment of Metastatic ER Positive, HER2 Negative Breast CancerRecruitingPhase 2Mayo ClinicNCT06525766Written as Capecitabine
See all 948 studies that test Capecitabine →
Given beside what is tested · 637 — Capecitabine is usual care or a partner of the new treatment
- Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)RecruitingPhase 1/2Merck Sharp & Dohme LLCNCT06469944Written as Capecitabine
- A Pilot Study Evaluating β-hydroxybutyrate Supplementation Concomitant to Short-Course Radiotherapy Followed by Immunotherapy Combined With CAPEOX Neoadjuvant Therapy in Patients With Locally Advanced Rectal CancerRecruitingPhase 2Tao ZhangNCT07239466Written as Capecitabine
- A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal CancerRecruitingPhase 1Astellas Pharma Global Development, Inc.NCT07024615Written as Capecitabine
- CR-001 in Adult Participants With Locally Advanced or Metastatic Solid TumorsRecruitingPhase 1/2Crescent Biopharma, Inc.NCT07335497Written as Capecitabine
- SCRT Combined With CAPOX and PD-1 Antibody Versus LCRT Combined With CAPOX for Early Low-lying Rectal Cancer (TORCH-E3)Not yet recruitingPhase 3Fudan UniversityNCT07933679Written as Capecitabine
- Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)RecruitingPhase 2Merck Sharp & Dohme LLCNCT06797635Written as Capecitabine
- Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ TrialRecruitingPhase 2National Cancer Institute (NCI)NCT03907475Written as Capecitabine
- A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)RecruitingPhase 3Merck Sharp & Dohme LLCNCT06966700Written as Capecitabine
- ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast CancerRecruitingPhase 2ALX Oncology Inc.NCT07007559Written as Capecitabine
- A Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric CancerRecruitingPhase 3Astellas Pharma Global Development, Inc.NCT07673887Written as Capecitabine
- Phase 1 Study of a Self-amplifying RNA Vaccine (ITI-5000) in Stage 2-3 Triple Negative Breast CancerRecruitingPhase 1Immunomic Therapeutics, Inc.NCT07652242Written as Capecitabine
- A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) and Pembrolizumab (MK-3475A) in Participants With Bladder Cancer (MK-2870-055)RecruitingPhase 3Merck Sharp & Dohme LLCNCT07829783Written as Capecitabine
- Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has SpreadRecruitingPhase 1/2Boehringer IngelheimNCT06324357Written as Capecitabine
- A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric CancerRecruitingPhase 3Astellas Pharma Global Development, Inc.NCT06901531Written as Capecitabine
- RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-PositiveRecruitingPhase 2/3Hoffmann-La RocheNCT07413939Written as Capecitabine
- Sintilimab Combined With LCCRT Followed by Capeox Chemotherapy in pMMR/MSS/MSI-L Locally Advanced Rectal CancerNot yet recruitingPhase 3Innovent Biologics (Suzhou) Co. Ltd.NCT07917468Written as Capecitabine
- D07001 Softgel-Capsules and Capecitabine Combination Therapy in Patients With Advanced Biliary Tract CancerRecruitingPhase 3InnoPharmax Inc.NCT06622057Written as Capecitabine
- Arginine-Restricted Diet Combined With Chemoradiotherapy in Neoadjuvant Rectal Cancer: A Phase Ib/II TrialNot yet recruitingPhase 1/2Xuelei Ma MDNCT07912346Written as CAPOX Chemotherapy
- Phase Ib/II Trial of Serine/Glycine-Restricted Diet With Chemoradiotherapy for Rectal CancerNot yet recruitingPhase 1/2Xuelei Ma MDNCT07912463Written as CAPOX Chemotherapy
- TRINITY TRIAL; Trial Of PRRT Plus CAPTEM Vs CAPTEM Alone In Well Differentiated GEP NETSNot yet recruitingPhase 3Tata Memorial HospitalNCT07910760Written as Capecitabine
Showing 20 of 637.
As the comparator · 151 — what is tested is compared with Capecitabine
- A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast CancerRecruitingPhase 1/2Hoffmann-La RocheNCT03424005Written as Capecitabine
- Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)RecruitingPhase 3Merck Sharp & Dohme LLCNCT06393374Written as Capecitabine
- Hepatic Arterial Infusion Chemotherapy Versus Capecitabine as Adjuvant Therapy for Resected Biliary Tract CancerNot yet recruitingPhase 3Zhai WenlongNCT07916844Written as Capecitabine
- Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)RecruitingPhase 3Gilead SciencesNCT05633654Written as Capecitabine
- A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)RecruitingPhase 3Merck Sharp & Dohme LLCNCT07060807Written as Capecitabine
- Neoadjuvant Radiotherapy for Rectal Adenocarcinoma With Capecitabine Versus TAS-102 (Neo-REACT): A Multi-center, Randomized, Phase III TrialRecruitingPhase 3Shandong Cancer Hospital and InstituteNCT06850090Written as Capecitabine
- A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)RecruitingPhase 3Merck Sharp & Dohme LLCNCT06312176Written as Capecitabine
- Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP TrialRecruitingPhase 3ECOG-ACRIN Cancer Research GroupNCT05863195Written as Capecitabine
- A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2RecruitingPhase 3RemeGen Co., Ltd.NCT04400695Written as Capecitabine Tablets
- First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2)RecruitingPhase 2Qilu Hospital of Shandong UniversityNCT06730373Written as Capecitabine
- A Prospective, Open-Label, Randomized Controlled Clinical Study Comparing Hepatic Arterial Infusion Chemotherapy (HAIC) With Capecitabine as Adjuvant Therapy After Radical Surgery for Malignant Biliary Tract TumorsRecruitingPhase 4Zhai WenlongNCT07790445Written as Capecitabine
- A Study of Trastuzumab Rezetecan in Combination With Adebrelimab Versus Investigator's Choice of Therapy in Subjects With Residual Triple Negative Breast CancerRecruitingPhase 3Suzhou Suncadia Biopharmaceuticals Co., Ltd.NCT07679360Written as Capecitabine tablets
- A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)RecruitingPhase 2/3Bristol-Myers SquibbNCT06926868Written as Capecitabine
- Anti-EGFR Agents in Patients With Right-sided Advanced Colorectal Cancer With Wild-type RAS and AREG/EREG High StatusNot yet recruitingPhase 4Gruppo Oncologico del Nord-OvestNCT07094893Written as Capecitabine
- A Study of BL-M07D1 Versus Physician's Choice of Chemotherapy in Patients With HER2-expressing Locally Advanced or Metastatic Biliary Tract Cancer After Platinum-containing Chemotherapy FailureRecruitingPhase 3Sichuan Baili Pharmaceutical Co., Ltd.NCT07606599Written as Capecitabine Tablets
- A Study Comparing BL-B01D1 With Treatment of Physician's Choice in Patients With Locally Advanced or Metastatic Biliary Tract Cancer After Failure of Platinum-based Chemotherapy(PANKU-BTC01)RecruitingPhase 3Sichuan Baili Pharmaceutical Co., Ltd.NCT07582315Written as Capecitabine
- A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+/HER2- Breast Cancer After Failure of Prior Endocrine Therapy(PANKU-Breast03)RecruitingPhase 3Sichuan Baili Pharmaceutical Co., Ltd.NCT07648914Written as Capecitabine
- Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.RecruitingPhase 3Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.NCT07385703Written as Capecitabine Tablets
- Sac-TMT Sequential Capecitabine Versus Capecitabine in Early-Stage High-Risk Triple-Negative Breast Cancer Without BRCA MutationsNot yet recruitingPhase 3Fudan UniversityNCT07628504Written as Capecitabine
- YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast CancerRecruitingPhase 3MediLink Therapeutics (Suzhou) Co., Ltd.NCT07461454Written as Capecitabine
Showing 20 of 151.
What changed recently
From the registry's own updates since Oct 15, 2026.
Results posted1
Newly registered2
- Feasibility Study of Huangqi Yangyuan Formula for Capecitabine-Induced Adverse Reactions in Advanced Colorectal CancerNov 3, 2026NCT07913516
- Fruquintinib Combined With Capecitabine as Adjuvant Extended Therapy After R0 Resection and Perioperative Chemotherapy in Patients With Liver-Only Metastatic Colorectal CancerOct 21, 2026NCT07885384
Codes
What other systems call Capecitabine · ClinicalTrials.gg INT006570
- MeSH (NLM) D000069287CapecitabineConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 6804DJ8Z9UCAPECITABINEConfirmed FDA, NLM, Wikidata
- RxNorm 194000Confirmed FDA, Wikidata
- Wikidata Q420207capecitabineConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C1794CapecitabineOne source FDA
- DrugBank DB01101One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000069287 | Capecitabine | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 6804DJ8Z9U | CAPECITABINE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 194000 | — | Confirmed FDA, Wikidata |
| Wikidata | Q420207 | capecitabine | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C1794 | Capecitabine | One source FDA |
| DrugBank | DB01101 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.